

## Supplementary references

- S1 Worldometers COVID-19 coronavirus pandemic. [www.worldometers.info/coronavirus/](http://www.worldometers.info/coronavirus/). Accessed 28<sup>th</sup> June 2020.
- S2 Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine* 2020;382:1708-1720.
- S3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* 2020
- S4. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. *Blood* 2019;133(9):906-918
- S5. Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID19 coagulopathy in Caucasian patients. *Br J Haematol* 2020;189(6):1044-1049
- S6. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020;18(4):844-847
- S7 Huisman A, Beun R, Sikma M, Westerink J, Kusadasi N. Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2. *Int J Lab Hematol* 2020; doi 10.1111/ijth.13244
- S8. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. *J Thromb Haemost* 2020; doi 10.1111/jth.14850
- S9. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. *J Thromb Haemost* 2020; doi 10.1111/jth.14854
- S10. Spiezia L, Boscolo A, Poletto F, et al. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. *Thromb Haemost* 2020;120(6):998-1000
- S11. Goshua G, Pine A, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. *Lancet Haematology* 2020
- S12. Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. *Intensive Care Med* 2020;46(6):1105-1108
- S13. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 2020;395(10234):1417-1418

- S14. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *Journal of Thrombosis and Haemostasis* 2020;18:1421-1424.
- S15. Desborough MJR, Doyle AJ, Griffiths A, et al. Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom. *Thromb Res* 2020;193:1-4
- S16. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis Research* 2020
- S17. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thrombosis Research* 2020;191:9-14
- S18. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *Journal of Thrombosis and Haemostasis* 2020; doi 10.1111/jth.14888
- S19. Thomas W, Varley J, Johnston A, et al. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. *Thromb Res* 2020;191:76-77
- S20. Poissy J, Goutay J, Caplan M, et al. Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence. *Circulation* 2020; doi 10.1161/CIRCULATIONAHA.120.047430
- S21. Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. *J Thromb Haemost* 2020; doi 10.1111/jth.14869
- S22. Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. *Thrombosis Research* 2020
- S23. Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive Care Med* 2015;41(8):1411-1423
- S24. Brandenburger T, Dimski T, Slowinski T, Kindgen-Milles D. Renal replacement therapy and anticoagulation. *Best Practice & Research Clinical Anaesthesiology* 2017;31(3):387-401
- S25. Wu MY, Hsu YH, Bai CH, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. *Am J Kidney Dis* 2012;59(6):810-818
- S26. Schilder L, Nurmohamed SA, Bosch FH, et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. *Crit Care* 2014;18(4):014-0472

- S27. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofiltration. *Crit Care Med* 2009;37(2):545-552
- S28. Selby NM, Forni LG, Laing CM, et al. Covid-19 and acute kidney injury in hospital: summary of NICE guidelines. *BMJ* 2020;369:m1963
- S29. Wu H, Larsen CP, Hernandez-Arroyo CF, et al. AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL1 High-Risk Genotype. *Journal of the American Society of Nephrology* 2020:ASN.2020050558
- S30. White D, MacDonald S, Bull T, et al. Heparin resistance in COVID-19 patients in the intensive care unit. *J Thromb Thrombolysis* 2020;22:1-5
- S31. Mitsuguro M, Okamoto A, Shironouchi Y, et al. Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin. *Int J Hematol* 2015;101(2):119-125
- S32. Guervil DJ, Rosenberg AF, Winterstein AG, et al. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. *Ann Pharmacother* 2011;45(7-8):861-868
- S33. Samuel S, Allison TA, Sharaf S, et al. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study. *J Clin Pharm Ther* 2016;41(5):499-502
- S34. Arachchillage DRJ, Kamani F, Deplano S, Banya W, Laffan M. Should we abandon the APTT for monitoring unfractionated heparin? *Thromb Res* 2017;157:157-161
- S35. Beun R, Kusadasi N, Sikma M, Westerink J, Huisman A. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2. *Int J Lab Hematol* 2020;42:19-20
- S36. Arachchillage DJ, Remington C, Rosenberg A, et al. Anticoagulation with Argatroban in patients with acute antithrombin deficiency in severe COVID -19. *British Journal of Haematology* 2020; doi 10.1111/bjh.16927
- S37. Chua HR, Laren GM, Choong LH, et al. Ensuring Sustainability of Continuous Kidney Replacement Therapy in the Face of Extraordinary Demand: Lessons From the COVID-19 Pandemic. *Am J Kidney Dis* 2020
- S38. Sourial MY, Sourial MH, Dalsan R, et al. Urgent Peritoneal Dialysis in Patients With COVID-19 and Acute Kidney Injury: A Single-Center Experience in a Time of Crisis in the United States. *American journal of kidney diseases : the official journal of the National Kidney Foundation* 2020:S0272-6386(0220)30735-30736